Reportlinker Adds Disease and Therapy Review: Urinary Incontinence

NEW YORK, April 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Disease and Therapy Review: Urinary Incontinence

http://www.reportlinker.com/p0191993/Disease-and-Therapy-Review-Urinary-Incontinence.html

The Urinary Incontinence Disease and Therapy Review provides an overview of the disease and related conditions, with prevalence information for the U.S., information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the urinary incontinence market, as well as sales of leading drugs and therapies are provided.

Table of contents

Overview

General description of the condition, including an overview of types

prevalence

Prevalence Table (Canada, US, Italy, Spain, Sweden, UK, India, Japan, Korea)

diagnosis

History

Physical examination

Testing

treatment

Non-pharmacological interventions

Treatment for total incontinence

Treatment for stress incontinence

Treatment for urge incontinence/ overactive bladder

Treatment for overflow incontinence

dosing and treatment costs

Dosing for commonly prescribed drugs

Costs for commonly prescribed drugs

market size

Overall market size

Sales information for key pharmaceuticals

comments

references/resources

To order this report:

: Disease and Therapy Review: Urinary Incontinence

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.